Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LODACA: Low-dose Decitabine in Refractory Aplastic Anemia
NCT04854889Phase 2Terminated
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine in aplastic anemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Started Apr 2021; status: terminated.
02
Drugs
decitabine
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT04854889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04854889.